Kyle T Darras, FNP-C | |
7500 University Dr, Bismarck, ND 58504-9634 | |
(701) 355-3770 | |
Not Available |
Full Name | Kyle T Darras |
---|---|
Gender | Female |
Speciality | |
Experience | Years |
Location | 7500 University Dr, Bismarck, North Dakota |
Accepts Medicare Assignments | Yes. She accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
Identifier | Type | State | Issuer |
---|---|---|---|
1235271388 | NPI | - | NPPES |
25358 | Other | ND | KYLE'S BCBS |
R26923 | Other | ND | STATE LIC# |
Taxonomy | Type | License (State) | Status |
---|---|---|---|
2085R0001X | Radiology - Radiation Oncology | R26923 (North Dakota) | Secondary |
363L00000X | Nurse Practitioner | R26923 (North Dakota) | Primary |
Mailing Address | Practice Location Address |
---|---|
Kyle T Darras, FNP-C Po Box 997, Bismarck, ND 58502-0997 Ph: (701) 530-7000 | Kyle T Darras, FNP-C 7500 University Dr, Bismarck, ND 58504-9634 Ph: (701) 355-3770 |
News Archive
VIVUS, Inc. today announced that the U.S. Food and Drug Administration Endocrinologic and Metabolic Drugs Advisory Committee recommended Qnexa be granted marketing approval by the FDA for the treatment of obesity in adults.
Cancer care will only improve by listening more to the experiences of patients and their carers, Health Minister Malcolm Chisholm said today. He was announcing £1.5 million of Executive funding for pioneering research into patient experiences at the University of Stirling's new Cancer Care Research Centre.
The U.S. Food and Drugs Administration (FDA) has approved tafluprost ophthalmic solution (Zioptan, Merck) 0.0015%, the first preservative-free prostaglandin analog ophthalmic solution for glaucoma.
In late December in San Antonio, Texas, a 36-year-old mother of three from Jefferson City, Missouri, gave her best friend the most precious gift of all: a healthy kidney and the promise of a new life for the New Year.
› Verified 9 days ago